The effectiveness of blocking GPIIa/IIIb in acute coronary syndromes may be partially attributed to its ability to bind conformationally active CD11b and inhibit Mac-1 mediated leukocyte adhesion [66]. Here, PECAM1 is linked to acute coronary syndrome.